Psychotropic Effects of COX-2 Inhibitors - A Possible New Approach for the Treatment of Psychiatric Disorders

Abstract

Cyclooxygenase-2 (COX-2) - constitutively expressed in the CNS - is suggested to have an important functional role in the CNS. COX-2 interacts with neurotransmitters such as acetylcholine, serotonin, and glutamate, but is also involved in the regulation of immune system and in inflammation in the central nervous system (CNS) via effects of prostaglandins, in particular prostaglandin E₂. Recently, a role for the new generation of selective COX-2 inhibitors in the treatment of psychiatric disorders is discussed.

Until now, COX-2 inhibitors have failed to show therapeutic effects in Alzheimer’s disease, but studies from basic research point to a possible effect on cognition. A clinical effect of the COX-2 inhibitor celecoxib on cognition was observed in schizophrenic patients. The therapeutic effect of celecoxib add-on treatment to the atypical antipsychotic risperidone, however, is not restricted to cognition.

A general effect on symptoms of schizophrenia was observed, which supports the view that an immunological/inflammatory process is involved in the pathogenesis of schizophrenia. In depression, however, signs of inflammation have been described since many years.

Although results of clinical studies with COX-2 inhibitors in depression are still lacking, clinical improvement of a depressive syndrome has been observed in patients, who have been treated with rofecoxib due to other indications. These preliminary clinical data are encouraging for therapeutic effects of the selective COX-2 inhibitors in psychiatric disorders, although these effects have to be confirmed in bigger clinical studies.

References

• 1 Aisen P S, Schafer K A, Grundman M, Pfeiffer E, Sano M, Davis K L, Farlow M R, Jin S, Thomas R G, Thal L J. Alzheimer's Disease Cooperative Study Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.  JAMA. 2003;  289 2819-2826
• 2 Andreasson K I, Savonenko A, Vidensky S, Goellner J J, Zhang Y, Shaffer A, Kaufmann W E, Worley P F, Isakson P, Markowska A L. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice.  J Neurosci. 2001;  21 8198-8209
• 3 Baik E J, Kim E J, Lee S H, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus.  Brain Res. 1999;  843 118-129
• 4 Berk M, Wadee A A, Kuschke R H, O'Neill K A. Acute phase proteins in major depression.  J Psychosom Res. 1997;  43 529-534
• 5 Breder C D, Saper C B. Expression of inductible cyclooxygenase in the central nervous system: implications for treatment of neurological disorders.  Curr Pharm Des. 2000;  6 1755-1776
• 6 Calabrese J R, Skwerer A G, Barana B, Gulledge A D, Valenzuela R, Butkus A, Subichin S, Krupp N E. Depression, immunocompetence, and prostaglandins of the E series.  Psychiatry Res. 1986;  17 41-47
• 7 Cao C, Matsumura K, Ozaki M, Watanabe Y. Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells.  J Neurosci. 1999;  19 716-725
• 8 Collantes-Esteves E, Fernandez-Perrez C h. Improved self-control of ostheoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.  Curr Med Res Opin. 2003;  19 402-410
• 9 Dantzer R, Bluthe R, Castanon N, Chauvet N, Capuron L, Goodall G, Kelley K W, Konsman J P, Layé S, Parnet P, Pousset F. Cytokine effects on behavior. In: Ader R, Felten DL, Cohen N (eds) Psychoneuroimmunology. Third Edition. Vol 2 San Diego; Academic Press 2001: pp 373-382
• 10 Dickerson F B, Boronow J J, Stallings C, Origoni A E, Ruslanova I, Yolken R H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia.  Arch Gen Psychiatry. 2003;  60 466-472
• 11 Giovannini M G, Scali C, Prosperi C, Bellucci A, Vannucchi M G, Rosi S, Pepeu G, Casamenti F. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway.  Neurobiol Dis. 2002;  11 257-274
• 12 Launer L J. Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: what next?.  JAMA. 2003;  289 2865-2867
• 13 Linnoila M, Whorton R, Rubinow D R, Cowdry R W, Ninan P T, Waters R N. CSF prostaglandin levels in depressed and schizophrenic patients.  Arch Gen Psychiatry. 1983;  40 405-406
• 14 Litherland S A, Xie X T, Hutson A D, Wasserfall C, Whittaker D S, She J -X, Hofig A, Dennis M A, Fuller K, Cook R, Schatz D, Moldawer L L, Clare-Salzler M J. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus.  J Clin Invest. 1999;  104 515-523
• 15 Maes M, Scharpe S, Meltzer H Y, Bosmans E, Suy E ., Calabrese J, Cosyns P. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression.  Psychiatry Res. 1993;  49 11-27
• 16 Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.  Cytokine. 1997;  9 853-858
• 17 McGeer P L. Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer’s disease.  Drugs Aging. 2000;  1 1-11
• 18 Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine-network in the CNS: implications for psychiatric disorders.  Prog Neuropsychopharmacol Biol Psychiat. 1998;  22 1-33
• 19 Müller N, Empel M, Riedel M, Schwarz M J, Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.  Eur Arch Psychiatry Clin Neurosci. 1997;  247 308-313
• 20 Müller N, Riedel M, Scheppach C, Brandstätter B, Sokkullu S, Krampe K, Ulmschneider M, Möller H -J, Schwarz M. Beneficial anti-psychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.  Am J Psychiatry. 2002;  159 1029-1034
• 21 Müller N, Riedel M, Schwarz M J, Engel R R. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci (in press)
• 22 Murray H J, O’Connor J J. A role for COX-2 and p38 mitogen activated protein kinase in long-term depression in the rat dentate gyrus in vitro.  Neuropharmacology. 2003;  44 374-380
• 23 Nishino S, Ueno R, Ohishi K, Sakai T, Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression.  Am J Psychiatry. 1989;  146 365-368
• 24 Nogawa S, Zhang F, Ross M E, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage.  J Neurosci. 1997;  17 2746-2755
• 25 O’Banion M K, Miller J C, Chang J W, Kaplan M D, Coleman P D. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures.  J Neurochem. 1996;  66 2532-2540
• 26 Pyeon D, Diaz F J, Splitter G A. Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus.  J Virol. 2000;  74 5740-5745
• 27 Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H. Different immune patterns in melancholic and non-melancholic major depression.  Eur Arch Psychiatry Clin Neurosci. 2001;  251 90-97
• 28 Sandrini M, Vitale G, Pini L A. Effect of rofecoxib on nociception and the serotonin system in the rat brain.  Inflamm Res. 51;  2002 154-159
• 29 Scali C, Giovannini M G, Prosperi C, Bellucci A, Pepeu G, Casamenti F. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo.  Neuroscience. 2003;  117 909-919
• 30 Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller P W, Portanova J, Lee J C, Dubinett S M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.  J Immunol. 2000;  164 361-370
• 31 Teunissen C E, van Boxtel M P, Bosma H, Bosmans E, Delanghe J, De Bruijn C, Wauters A, Maes M, Jolles J, Steinbusch H W, de Vente J. Inflammation markers in relation to cognition in a healthy aging population.  J Neuroimmunol. 2003;  134 142-150
• 32 van West D, Maes M. Activation of the inflammatory response system: A new look at the etiopathogenesis of major depression.  Neuroendocrinol Lett. 1999;  20 11-17
• 33 Vidensky S, Zhang Y, hand T, Goellner J, Shaffer A, Isakson P, Andreasson K. Neuronal overexpression of COX-2 results in dominant production of PGE₂ and altered fever response.  Neuromolecular Med. 2003;  3 15-28
• 34 Yaksh T L, Dirig D M, Conway C M, Svensson C, Luo Z D, Isakson P C. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E₂ is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1.  J Neurosci. 2001;  21 5847-5853
• 35 Yermakova A, O’Banion M K. Cyclooxygenases in the central nervous system: Implications for treatment of neurological disorders.  Curr Pharmaceutical Design. 2000;  6 1755-1776